Apparently, a few things, so buckle up.
As many of you know, Bob Marley was no stranger to cannabis.
The autodidact spent many a year enjoying the festivals, the crowd, and the reefer to his heart’s content. So too, it seems, the legacy continues through his kin.
Damian Marley, through his unique Stony Hill Corp. (OTCQB: STNY) brand, wishes to propagate that legacy with a little help from corporate America and the intelligentsia. On the surface, the matchup between reggae legend and scientist/doctor may seem far-fetched, but upon closer inspection, it makes all the sense in the world.
Stony Hill Corp. (www.stonyhillcorp.com), founded by Damian Marley, is a diversified company focused on multiple areas of the cannabis, hemp and CBD industry.
The company is focused on select investment, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceutical, as well as media industries.
One of Stony Hill’s recent announcements, which was quietly released and most likely not on most canna-investors radars yet, was that they just launched a line of hemp-derived CBD products. What’s interesting about this launch is not that the product offering is so broad, offering roughly 14 SKU’s, but that the CBD is hemp derived.
According to their press release from October 24th, 2017 they allude to the fact that being hemp-derived may help them in their expansion efforts as they may not be affected by the same interstate and federal export laws cannabis-derived Companies face—in other words, they could manufacture in one state, and sell throughout the US, the rest of North America and globally with no issues—cannabis-based players are marooned in the State they operate in.
It is these CBD products we see the connection to STNY’s Advisory board with their illustrious medical backgrounds. CBD is said to be a compound with many medical uses stretching from inflammation reduction to pain management, and the only way to make these claims is with true medical research.
Enter Dr. James Mulé, recognized for his research and clinical trial contributions to cancer immunotherapy over the years, particularly as they apply to melanoma. With professional degrees from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington he looks to take this company to the next level.
- The company Stony Hill is currently traded under ticker symbol OTCQB: STNY.
While thinly traded, it currently sits at $2.38/share with some steady support. We anticipate a potential skyrocketing share price due in part to the small float and thinly traded nature of the shares. The information we present to you here as yet to be disseminated to a broader audience, so consider yourselves early.
- Fun Fact: Dr. Mulé in his translational work in this area has helped to develop new treatments for advanced cancer patients.
His pedigree and background stretch out beyond even that. Image the potential for synergy and opportunity – particularly as legislation changes – to capitalize on this company’s potential if only at the pharmaceutical level.
Additionally, Dr. Mulé also received his formal post-graduate training at the Surgery Branch, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland. Pedigree like this is hard to come by in the OTC/Small Cap arena.
“This key addition to the team of Dr. Mulé is something other smaller cap companies could only dream of”
As if that’s not enough the company also has a Professor and another Ph.D. on board as well…
Professor Oded Shoseyov
is a Co-Founder of SP Nano Ltd. and serves as its Scientific Advisor. Prof. Shoseyov is the Scientific Founder of CBD Technologies., FuturaGene, Melodea, and Bondex.
Dr. Raymond Urbanski
Dr. Raymond W. Urbanski, M.D., Ph.D. has been Chief Medical Officer at GT Biopharma, Inc. since September 2017. Dr. Urbanski oversees the development of key products in GT Biopharma’s product pipeline, including its platform targeted immunotherapy BiKE and TriKE technologies.
So it seems, Bob Marley’s son and a former medical officer at Pfizer apparently have plenty in common. Who knew?
But we digress, small-cap stocks can in fact often be a gamble. However, from what we have seen thus far, Stony Hill Corp (OTCQB: STNY) is on another level entirely.
A positive PR pipeline may ensue and bring further awareness of the company’s shares. With thinly traded stocks like this, explosive moves are not uncommon.
Seriously Speaking, if they can capture even a fraction of the market for treating serious diseases etc through the use of their product, the shares should catapult and leave investors knowing that “Everything little thing, it’s gonna be alright.”
Image source: Shutterstock
The Cannabis Investor is a leading media outlet for Cannabis investment opportunities and breaking industry news.
Join our text message list:
USA: Text potstocks to 313131 to join
CDN: Text potstocks to 393939 to join
Join our email list here: http://eepurl.com/bUSa71
Follow The Cannabis Investor on Social Media
Stony Hill Corp. is a paid client of The Cannabis Investor.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.